Maryse Power

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels

Donna L. Forrest, Shannon Trainor, Ryan R. Brinkman et al. · Leukemia Research · 2008 · 81 citations

Life Sciences, Hematology, Oncology +11

Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma

Fong Chun Chan, Anja Mottok, Alina S. Gerrie et al. · Journal of Clinical Oncology · 2017 · 57 citations · Full text

Life Sciences, Oncology, Pathology +17

Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma

Alina S. Gerrie, Maryse Power, John D. Shepherd et al. · Annals of Oncology · 2014 · 50 citations · Full text

Medicine, Oncology, Chemotherapy +15

Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma

Alden A. Moccia, Felicitas Hitz, Paul Hoskins et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 47 citations

Medicine, Hematology, Oncology +17

Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation

Haowei Sun, Kerry J. Savage, Aly Karsan et al. · Clinical Lymphoma Myeloma & Leukemia · 2015 · 44 citations

Medicine, Hematology, Oncology +17